Advertisement
U.S. markets open in 4 hours 3 minutes

ChromaDex Corporation (CDXC)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.52000.0000 (0.00%)
At close: 04:00PM EST
1.5500 +0.03 (+1.97%)
Pre-Market: 04:00AM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Fast Stochastic

Fast Stochastic

Previous Close1.5200
Open1.5600
Bid0.0000 x 3100
Ask0.0000 x 1800
Day's Range1.4800 - 1.5750
52 Week Range1.2500 - 1.9900
Volume109,592
Avg. Volume67,928
Market Cap114.189M
Beta (5Y Monthly)1.86
PE Ratio (TTM)N/A
EPS (TTM)-0.0900
Earnings DateMar 06, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.85
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for CDXC

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • ChromaDex Corporation
    Daily – Vickers Top Buyers & Sellers for 02/22/2024The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    23 hours agoArgus Research
View more
  • Business Wire

    ChromaDex to Report Fourth Quarter 2023 Financial Results on Wednesday, March 6, 2024

    LOS ANGELES, February 21, 2024--ChromaDex Corp. (NASDAQ:CDXC) ("the Company"), a global bioscience company dedicated to healthy aging, announced that it will hold a conference call on Wednesday, March 6, 2024 at 4:30 p.m. ET to discuss its financial results for the fourth quarter, which ended December 31, 2023. The financial results will be reported in a press release after the close of regular stock market trading hours on the same day as the conference call.

  • Business Wire

    ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow on Monday, February 12, 2024

    LOS ANGELES, February 05, 2024--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, announced today that it will be participating in Renmark Financial Communications Inc.’s live Virtual Non-Deal Roadshow Series to discuss its latest investor presentation on Monday, February 12, 2024, at 11:00 AM PST. ChromaDex welcomes stakeholders, investors, and other individual followers to register and attend this live event.

  • Business Wire

    ChromaDex to Present at the Lytham Partners 2024 Investor Select Conference

    LOS ANGELES, January 26, 2024--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Brianna Gerber, will be participating in the Lytham Partners 2024 Investor Select Conference.